(2-fluoromethoxy-5-(5-trifluoromethyltetrazol-1-yl)benzyl)(2-phenylpiperidin-3-yl)amine
Peptideexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 27, 2004 (NCT00088738)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tachykinin-3AGONIST
TAC3 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- (18f)-(2-fluoromethoxy-5-(5-trifluoromethyltetrazol-1-yl)benzyl)(2-phenylpiperidin-3-yl)amine
- (18f)spa-rq
- (2-fluoromethoxy-5-(5-trifluoromethyltetrazol-1-yl)benzyl)(2-phenylpiperidin-3-yl)amine
- spa-rq
- spa-rq
- spa-rq
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00088738 | Phase 1 | Jul 27, 2004 | National Institute of Mental Health (NIMH) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Mental Health (NIMH) | Government | 1 | 1 | 1 | 2004 |
1 organizations
Page 1 / 1